Cite
Safety of Janus kinase (JAK) inhibitors in the short‐term treatment of atopic dermatitis.
MLA
Wood, Hannah, et al. “Safety of Janus Kinase (JAK) Inhibitors in the Short‐term Treatment of Atopic Dermatitis.” International Journal of Dermatology, vol. 61, no. 6, June 2022, pp. 746–54. EBSCOhost, https://doi.org/10.1111/ijd.15853.
APA
Wood, H., Chandler, A., Nezamololama, N., Papp, K., & Gooderham, M. J. (2022). Safety of Janus kinase (JAK) inhibitors in the short‐term treatment of atopic dermatitis. International Journal of Dermatology, 61(6), 746–754. https://doi.org/10.1111/ijd.15853
Chicago
Wood, Hannah, Antoinette Chandler, Novin Nezamololama, Kim Papp, and Melinda J. Gooderham. 2022. “Safety of Janus Kinase (JAK) Inhibitors in the Short‐term Treatment of Atopic Dermatitis.” International Journal of Dermatology 61 (6): 746–54. doi:10.1111/ijd.15853.